Withthe availability of the monoclonal antibody trastuzumab as an effective therapy formetastatic breast cancer, there is an increased need to evaluate HER2 status toidentify those patients who might benefit from this treatment and to monitor diseaseprogression. Here, ERBB2 is linked to breast carcinoma.